Abstract
The presence of amyloid fibrils of α-synuclein is closely associated with Parkinson’s disease and related synucleinopathies. It is still very challenging, however, to systematically discover small molecules that prevent the formation of these aberrant aggregates. Here, we describe a structure-based approach to identify small molecules that specifically inhibit the surface-catalyzed secondary nucleation step in the aggregation of α-synuclein by binding to the surface of the amyloid fibrils. The resulting small molecules are screened using a combination of kinetic and thermodynamic assays for their ability to bind α-synuclein fibrils and prevent the further generation of toxic oligomers. This study demonstrates that the combination of structure-based and kinetic-based drug discovery methods can lead to the identification of small molecules that selectively inhibit the autocatalytic proliferation of α-synuclein aggregates.
Introduction
Parkinson’s disease and other synucleinopathies are characterized by the misfolding and aggregation of $\alpha$-synuclein ($\alpha$S) into amyloid fibrils. While these large aggregates are a hallmark of the disease, current research suggests that smaller, transient species known as oligomers are the primary drivers of neurotoxicity. A critical challenge in therapeutic development is the autocatalytic nature of $\alpha$S aggregation: once fibrils are present, their surfaces act as templates for the formation of new aggregates through a process called secondary nucleation. This creates a runaway feedback loop that rapidly increases the concentration of toxic species.
This study addresses the need for a rational discovery process that combines structural modeling with experimental kinetic validation to identify small molecules that can shut down these "catalytic factories."
Methodology: An "In Silico to In Vitro" Pipeline
The researchers employed a multi-stage screening pipeline to identify molecules capable of binding to the fibril surface:
- Binding Site Identification: Using the
Fpocketalgorithm on the cryo-EM structure of an $\alpha$S fibril (PDB: 6cu7), the team identified a specific pocket involving residues His50 and Glu57. This site was targeted because $\alpha$S aggregation is highly pH-dependent, suggesting that the protonation of Histidine plays a key role in the catalytic surface. - Virtual Screening and Filtering: A library of approximately 230 million compounds from the ZINC database was filtered using Central Nervous System Multiparameter Optimization (CNS MPO) criteria to ensure potential blood-brain barrier permeability, narrowing the pool to 2 million candidates.
- Consensus Docking: Two docking programs,
AutoDock VinaandFRED, were used to rank the molecules. The top 1,000 consensus hits were clustered by chemical similarity (Tanimoto clustering), resulting in 79 representative "centroid" molecules for experimental testing. - Kinetic and Biophysical Validation: 67 compounds were subjected to Thioflavin T (ThT) fluorescence assays to monitor aggregation kinetics. Promising hits were further characterized using Transmission Electron Microscopy (TEM), Mass Spectrometry, and Fluorescence Polarization to determine binding affinities ($K_d$).
Key Results and Insights
The screening process successfully identified several potent inhibitors, most notably Compound C.
Inhibition of Secondary Nucleation
Kinetic analysis revealed that Compound C significantly increases the half-time ($t_{1/2}$) of $\alpha$S aggregation—by approximately 3.5-fold at 10 molar equivalents. Crucially, mathematical modeling of the kinetic data showed that Compound C specifically targets the fibril amplification rate (inhibiting it by up to 87%) while having a negligible effect on the elongation of existing fibrils. This confirms the molecule's specific action against the surface-catalyzed secondary nucleation process rather than simple growth inhibition.
Binding Affinity and Selectivity
Fluorescence polarization assays confirmed that Compound C binds to $\alpha$S fibrils with a dissociation constant ($K_d$) of approximately 4 $\mu$M. Furthermore, the compound showed high selectivity for $\alpha$S over $A\beta42$ fibrils (associated with Alzheimer’s disease), indicating that it recognizes structural features unique to the $\alpha$-synuclein polymorph.
Discussion and Future Directions
This research highlights the importance of targeting the "sides" of amyloid fibrils rather than just their "ends." By neutralizing the catalytic surface of $\alpha$S fibrils, it is possible to stop the production of toxic oligomers at the source. The focus on the His50-containing pocket provides a structural rationale for the pH-sensitivity of $\alpha$S aggregation and offers a specific site for future optimization.
While the study was conducted in vitro, the use of CNS MPO filters during the screening process increases the likelihood that these leads can be developed into brain-penetrant drugs. However, the authors acknowledge that $\alpha$S fibrils are polymorphic; a molecule that binds one shape (like the 6cu7 polymorph used here) might not bind others found in different disease stages. Future work will focus on testing these inhibitors in cellular and animal models and exploring their potential as diagnostic radiotracers for early-stage detection of synucleinopathies.
Conclusion
By combining high-throughput computational docking with rigorous kinetic validation, this study establishes a robust pipeline for the discovery of "anti-autocatalytic" drugs. The identification of Compound C as a potent and selective inhibitor of $\alpha$-synuclein secondary nucleation represents a significant step toward rational therapies for Parkinson’s disease.
Summary updated